These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34218785)

  • 1. New Pharmacological Targets for the Treatment of Schizophrenia: A Literature Review.
    Ventriglio A; Bellomo A; Ricci F; Magnifico G; Rinaldi A; Borraccino L; Piccininni C; Cuoco F; Gianfelice G; Fornaro M; Delle Monache S; De Berardis D
    Curr Top Med Chem; 2021 Oct; 21(16):1500-1516. PubMed ID: 34218785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.
    de Bartolomeis A; Fiore G; Iasevoli F
    Curr Pharm Des; 2005; 11(27):3561-94. PubMed ID: 16248808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.
    Chaves C; Marque CR; Trzesniak C; Machado de Sousa JP; Zuardi AW; Crippa JA; Dursun SM; Hallak JE
    Braz J Med Biol Res; 2009 Nov; 42(11):1002-14. PubMed ID: 19855900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
    Kolomeets NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.
    Dogra S; Conn PJ
    Mol Pharmacol; 2022 May; 101(5):275-285. PubMed ID: 35246479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development.
    Müller N
    Expert Opin Ther Targets; 2008 Dec; 12(12):1497-507. PubMed ID: 19007319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMDA pathology and treatment of schizophrenia.
    Chang HJ; Lane HY; Tsai GE
    Curr Pharm Des; 2014; 20(32):5118-26. PubMed ID: 24410561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.
    Paz RD; Tardito S; Atzori M; Tseng KY
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):773-86. PubMed ID: 18650071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia.
    Okubo R; Okada M; Motomura E
    Biomolecules; 2024 Sep; 14(9):. PubMed ID: 39334894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
    Singh SP; Singh V
    CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of NMDA receptors in new treatments for schizophrenia.
    Hashimoto K
    Expert Opin Ther Targets; 2014 Sep; 18(9):1049-63. PubMed ID: 24965576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.
    Noetzel MJ; Jones CK; Conn PJ
    Discov Med; 2012 Nov; 14(78):335-43. PubMed ID: 23200065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
    Javitt DC
    Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update.
    Cadinu D; Grayson B; Podda G; Harte MK; Doostdar N; Neill JC
    Neuropharmacology; 2018 Nov; 142():41-62. PubMed ID: 29196183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.
    Goff DC
    Curr Neuropharmacol; 2017; 15(1):21-34. PubMed ID: 26915421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.